OpenNashEarnings

Zimmer Biomet (ZBH) · Medical Devices

Zimmer Biomet Q2 2026 earnings: summary, key numbers & outlook

Results filed 5 Aug 2026 · Quarter ended 30 Jun 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Zimmer Biomet cleared its next-generation ROSA Shoulder System and raised full-year guidance as go-to-market changes and its innovation cycle gain traction.

Zimmer Biomet received U.S. FDA 510(k) clearance for the next generation ROSA Shoulder System and completed first cases. The company says it is the first in the industry to support both glenoid and humeral bone preparation for anatomic and reverse techniques. Technology & Data, Bone Cement and Surgical sales grew 21.1%, while hips grew 5.0% and knees were flat.

Management is steering toward what CEO Ivan Tornos calls the boldest leader in MedTech, through commercial transformation and its innovation cycle. It is also raising share repurchase expectations to up to $1 billion for 2026. The tension is that knees, the largest category, are barely growing, and the sales network transformation and product rationalization carry execution risk.

Key numbers

Net earnings · GAAP
$198.3 million

Diluted EPS · GAAP
$1.03

up 33.8%

Adjusted diluted EPS · non-GAAP
$2.07

consistent with the prior year period

Gross margin · GAAP
63.3%

vs. 63.8% a year ago

Operating profit · GAAP
$326.1M

vs. $300.0 million a year ago

Operating profit margin · GAAP
15.0%

vs. 14.4% a year ago

Operating cash flow · GAAP
$447.9 million

Free cash flow · non-GAAP
$308.3 million

Segment or metricValueChange
United States net sales$1.2Bup 5.6% reported; 4.6% organic constant currency
International net sales937.0Mup 3.7% reported; 3.1% organic constant currency
Knees828.9Mup 0.4% reported; 0.1% constant currency
Hips562.7Mup 5.0% reported; 5.1% constant currency
S.E.T. (Sports Medicine, Extremities, Trauma, CMF, Thoracic)586.0Mup 6.4% reported; 3.4% organic constant currency
Technology & Data, Bone Cement and Surgical199.4Mup 21.1% reported; 21.5% constant currency
Where each number comes from
  • Net earnings: “Net earnings for the second quarter were $198.3 million, or $399.6 million on an adjusted1 basis.”
  • Diluted EPS: “Diluted earnings per share were $1.03 for the second quarter, an increase of 33.8%, and adjusted1 diluted earnings per share were $2.07”
  • Adjusted diluted EPS: “adjusted1 diluted earnings per share were $2.07, consistent with the prior year period.”
  • Gross margin: “Gross margin | 63.3% | 63.8% | 63.9% | 63.5%”
  • Operating profit: “Acquisition, integration, divestiture and related | 18.1 | 78.9 Operating expenses | 1,850.9 | 1,777.3 Operating Profit | 326.1 | 300.0”
  • Operating profit margin: “Operating profit margin | 15.0% | 14.4% | 16.4% | 14.9%”
  • Operating cash flow: “Zimmer Biomet generated $447.9 million in operating cash flow and $308.3 million of free cash flow1 in the second quarter.”
  • Free cash flow: “Zimmer Biomet generated $447.9 million in operating cash flow and $308.3 million of free cash flow1 in the second quarter.”
  • United States net sales: “United States | $1,239.9 | 5.6% | 5.6% | 4.6% International | 937.0 | 3.7 | 3.5 | 3.1 Total | $2,177.0 | 4.8% | 4.7% | 4.0%”
  • International net sales: “United States | $1,239.9 | 5.6% | 5.6% | 4.6% International | 937.0 | 3.7 | 3.5 | 3.1 Total | $2,177.0 | 4.8% | 4.7% | 4.0%”
  • Knees: “Knees United States | $455.0 | 1.4% | 1.4% | 1.4% International | 374.0 | (0.9) | (1.5) | (1.5) Total | 828.9 | 0.4 | 0.1 | 0.1”
  • Hips: “Hips United States | 288.5 | 5.9 | 5.9 | 5.9 International | 274.1 | 4.0 | 4.2 | 4.2 Total | 562.7 | 5.0 | 5.1 | 5.1”
  • S.E.T. (Sports Medicine, Extremities, Trauma, CMF, Thoracic): “S.E.T. * | 586.0 | 6.4 | 6.2 | 3.4 Technology & Data, Bone Cement and Surgical | 199.4 | 21.1 | 21.5 | 21.5”
  • Technology & Data, Bone Cement and Surgical: “S.E.T. * | 586.0 | 6.4 | 6.2 | 3.4 Technology & Data, Bone Cement and Surgical | 199.4 | 21.1 | 21.5 | 21.5”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 2026vs year agovs last quarter
Revenue$2.2B+4.8%+4.3%
Operating income$326.1M+8.7%−12.6%
Net income$198.3M+29.8%−16.7%
Diluted EPS$1.03+33.8%−15.6%
Free cash flow$393.6M+20.0%+21.8%
Operating margin15.0%+0.6 pts−2.9 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Reported revenue changeyear ending December 31, 2026 (reported revenue change)3.9% - 4.9%
Constant currency revenue changeyear ending December 31, 2026 (constant currency revenue change)3.4% - 4.4%
Organic constant currency revenue changeyear ending December 31, 2026 (organic constant currency revenue change)2.25% - 3.25%
Adjusted diluted EPSyear ending December 31, 2026$8.47 - $8.59

Key takeaways

  1. Next-generation ROSA Shoulder System cleared and in first cases

    Zimmer Biomet received FDA 510(k) clearance and completed first cases of the system, which supports both glenoid and humeral bone preparation for anatomic and reverse techniques. It extends the ROSA robotics platform into shoulders.

  2. Technology, bone cement and surgical lines grew fastest

    The Technology & Data, Bone Cement and Surgical category grew 21.1%, far ahead of other categories. This points to demand for the company's technology-linked offerings.

  3. Knees were nearly flat despite robotics recognition

    Knees grew 0.4% reported, with U.S. up 1.4% and International down 0.9%. ROSA Knee with OptimiZe won a 2026 MedTech Breakthrough Award, but the largest category is not yet showing growth.

  4. Hips grew 5.0%, led by the United States

    U.S. hips grew 5.9% and international hips 4.0%. Hips are a steady contributor alongside the technology-linked categories.

  5. Guidance raised on go-to-market progress and innovation

    Management raised full-year revenue and adjusted EPS guidance, citing a strong first half, healthy underlying markets, go-to-market changes progressing as planned and momentum from its innovation cycle. It also raised its 2026 buyback expectation to up to $1 billion.

Charts

Revenue$2.2B+4.8% y/yQ2 2026
Q4 2024: $2.0B (worked out from the annual figure)Q4 ’24$2.0BQ1 2025: $1.9BQ1 ’25$1.9BQ2 2025: $2.1BQ2 ’25$2.1BQ3 2025: $2.0BQ3 ’25$2.0BQ4 2025: $2.2B (worked out from the annual figure)Q4 ’25$2.2BQ1 2026: $2.1BQ1 ’26$2.1BQ2 2026: $2.2BQ2 ’26$2.2BQ3 2026: $2.1BQ3 ’26$2.1B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$2.0B *
Q1 2025$1.9B
Q2 2025$2.1B
Q3 2025$2.0B
Q4 2025$2.2B *
Q1 2026$2.1B
Q2 2026$2.2B
Q3 2026$2.1B
Diluted EPS (GAAP)$1.03+33.8% y/yQ2 2026
Q1 2025: $0.91Q1 ’25$0.91Q2 2025: $0.77Q2 ’25$0.77Q3 2025: $1.16Q3 ’25$1.16Q1 2026: $1.22Q1 ’26$1.22Q2 2026: $1.03Q2 ’26$1.03Q3 2026: $1.00Q3 ’26$1.00
Data
Q1 2025$0.91
Q2 2025$0.77
Q3 2025$1.16
Q1 2026$1.22
Q2 2026$1.03
Q3 2026$1.00

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin15.0%+0.6 pts y/yQ2 2026
Q4 2024: 19.2%Q4 ’2419.2%Q1 2025: 15.3%Q1 ’2515.3%Q2 2025: 14.4%Q2 ’2514.4%Q3 2025: 17.6%Q3 ’2517.6%Q4 2025: 6.9%Q4 ’256.9%Q1 2026: 17.9%Q1 ’2617.9%Q2 2026: 15.0%Q2 ’2615.0%Q3 2026: 14.9%Q3 ’2614.9%
Data
Q4 202419.2%
Q1 202515.3%
Q2 202514.4%
Q3 202517.6%
Q4 20256.9%
Q1 202617.9%
Q2 202615.0%
Q3 202614.9%
Free cash flow$393.6M+20.0% y/yQ2 2026
Q4 2024: $454.8MQ4 ’24$454.8MQ1 2025: $338.2MQ1 ’25$338.2MQ2 2025: $328.1MQ2 ’25$328.1MQ3 2025: $363.7MQ3 ’25$363.7MQ4 2025: $442.6MQ4 ’25$442.6MQ1 2026: $323.1MQ1 ’26$323.1MQ2 2026: $393.6MQ2 ’26$393.6MQ3 2026: $484.2MQ3 ’26$484.2M
Data
Q4 2024$454.8M
Q1 2025$338.2M
Q2 2025$328.1M
Q3 2025$363.7M
Q4 2025$442.6M
Q1 2026$323.1M
Q2 2026$393.6M
Q3 2026$484.2M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What did Zimmer Biomet launch this quarter?

It received FDA 510(k) clearance for the next generation ROSA Shoulder System and completed first cases. The company describes it as the first in the industry to support both glenoid and humeral bone preparation for anatomic and reverse techniques.

Which product categories drove growth?

Technology & Data, Bone Cement and Surgical grew 21.1% and hips grew 5.0%. Knees grew only 0.4% reported.

What is management's strategic message?

CEO Ivan Tornos said go-to-market changes are progressing as planned and the innovation cycle has momentum. He said the company aims to build the boldest leader in MedTech and deliver consistent, durable growth.

How is the company using its capital?

It raised its 2026 share repurchase expectation to up to $1 billion. It repurchased $500.8 million of common stock in the first six months.

Is there any leadership change in the quarter?

Chintan Desai was named president of the Asia Pacific Region, replacing Sang Yi, who departs on Aug. 28.

Documents

SEC filing